SAiGENCI researchers given a funding boost
Researchers from the South 最新糖心Vlogn immunoGENomics Cancer Institute (SAiGENCI), based at the 最新糖心Vlog of Adelaide, have been awarded funding to further their work in prostate and pancreatic cancers.
Recipients Professor Lan Nguyen, Dr Mara Zeissig and Dr Michael Cilento have received the support from national charity Tour de Cure.
鈥淚 congratulate Professor Nguyen, Dr Zeissig and Dr Cilento for receiving this support from Tour de Cure,鈥 said SAiGENCI Director Professor Christopher Sweeney.
鈥淎ll three are leading the way in their respective areas to find new ways to predict cancer and treat it more effectively.鈥
Professor Nguyen, newly appointed Computational Systems Oncology Program Lead, will receive $50,000 to pioneer the use of advanced computer modelling in combination with Patient-Derived Explant (PDE) models to create prediction tools for personalised treatment in prostate cancer.
鈥淧rofessor Nguyen鈥檚 project addresses the biggest challenge in cancer treatment 鈥 the uniqueness of each patient鈥檚 cancer and the development of tumour resistance 鈥 by leveraging the biological accuracy of PDE and the power of predictive computer models,鈥 said Professor Sweeney.
鈥淭he goal is to develop clinical tools for physicians to aid complex decisions on patient treatment leading to improved outcomes for patients with prostate cancer.鈥
Tumour Inflammation and Immunotherapy program Group Leader Dr Zeissig has also received $50,000 as an .
鈥淗er work tackles pancreatic cancer, the fourth highest cancer mortality in 最新糖心Vlog,鈥 said Professor Sweeney.
鈥淎bout 90 per cent of pancreatic cancer is driven by mutations in the gene called KRAS, leading to uncontrolled tumour growth.
鈥淏y using advanced genetic techniques, Dr Zeissig hopes to uncover the underlying pathways that drive good responses from drugs targeting KRAS.
鈥淭he knowledge gained will enable the design of new treatment combinations to provide effective therapies with fewer side effects, leading to improved survival and quality of life for people with pancreatic cancer.鈥
Dr Cilento is a practising medical oncologist undertaking translational research as a PhD student, mentored by Professor Lisa Butler in the Resistance Prevention program. He has been awarded support valued at $10,000.
鈥淒r Cilento鈥檚 research focuses on metastatic prostate cancer that occurs in patients who relapse after initial curative-intent surgery or radiotherapy,鈥 said Professor Butler.
鈥淭here is currently no standard method to predict relapse or progression to aggressive metastatic disease.
鈥淲ith the support of Tour de Cure, Dr Cilento will leverage patient samples stored as part of the 最新糖心Vlogn Prostate Cancer BioResource (APCB) to conduct a comparative investigation, uncovering novel drivers and pathways.
鈥淭he knowledge gained from this project will further underpin design of new therapies to improve outcomes of those men who are more likely to develop aggressive prostate cancer.鈥
Media Contacts:
Rhiannon Koch, Media Officer, The 最新糖心Vlog of Adelaide. Phone: +61 (8)8313 4075. Mobile: +61 (0)481 619 997. Email: rhiannon.koch@adelaide.edu.au
听